GAA
CRSP icon

Global Assets Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Global Assets Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
4,010
-350
-8% -$18.4K 0.05% 306
2026
Q1 		$207K Buy
4,360
+10
+0.2% +$527 0.06% 209
2025
Q4 		$228K Buy
+4,350
New +$261K 0.07% 255

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Global Assets Advisory's CRSP Position: Q2 2026 in Review

Global Assets Advisory reduced its CRISPR Therapeutics (CRSP) stake by 8% in Q2 2026, selling an estimated $18.4K and leaving 4,010 shares worth $222K. The position accounts for 0.05% of the portfolio, ranked #306.

Global Assets Advisory first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $228K in Q4 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Global Assets Advisory held 4,010 shares of CRISPR Therapeutics worth $222K as of Q2 2026.
  • Global Assets Advisory sold 350 CRISPR Therapeutics shares in Q2 2026, an estimated $18.4K.
  • CRISPR Therapeutics made up 0.05% of Global Assets Advisory's portfolio in Q2 2026, its #306 holding.
  • Global Assets Advisory first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Global Assets Advisory's CRISPR Therapeutics position peaked at $228K in Q4 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Global Assets Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.